FIDELIO-DKD (2020) — Trial Summary

FIDELIO-DKD (2020): Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduced risk of kidney failure and cardiovascular events in patients with type 2 diabetes and CKD.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.